PGE2 works through four distinct G protein-coupled E-prostanoid receptors, EP1 to EP4, and a growing number of studies suggest that PGE2 exerts neurotoxic effects by binding to EP1, EP2 or EP3 receptors in models of chronic neurodegenerative disease like Alzheimer’s disease (AD) and Parkinson’s disease [29, 30]. Here, PTGER1 is linked to Parkinson disease.